Trial Watch: experimental TLR7/TLR8 agonists for oncological indications

Giorgio Frega, Qi Wu, Julie Le Naour, Erika Vacchelli, Lorenzo Galluzzi, Guido Kroemer, Oliver Kepp

    Résultats de recherche: Contribution à un journalArticle 'review'Revue par des pairs

    72 Citations (Scopus)

    Résumé

    Resiquimod (R848) and motolimod (VTX-2337) are second-generation experimental derivatives of imiquimod, an imidazoquinoline with immunostimulatory properties originally approved by the US Food and Drug Administration for the topical treatment of actinic keratosis and genital warts more than 20 years ago. Both resiquimod and motolimod operate as agonists of Toll-like receptor 7 (TLR7) and/or TLR8, in thus far delivering adjuvant-like signals to antigen-presenting cells (APCs). In line with such an activity, these compounds are currently investigated as immunostimulatory agents for the treatment of various malignancies, especially in combination with peptide-based, dendritic cell-based, cancer cell lysate-based, or DNA-based vaccines. Here, we summarize preclinical and clinical evidence recently collected to support the development of resiquimod and motolimod and other TLR7/TLR8 agonists as anticancer agents.

    langue originaleAnglais
    Numéro d'article1796002
    journalOncoImmunology
    Volume9
    Numéro de publication1
    Les DOIs
    étatPublié - 1 janv. 2020

    Contient cette citation